ABSTRACT
At present, there are various treatment methods for hepatocellular carcinoma (HCC), including surgical treatment, interventional treatment, and immunotherapy, and even so, the five-year survival rate of HCC patients is only 12.5%. Influencing factors for the prognosis of HCC have always been the focus of research. With the in-depth research on programmed cell death protein 1 (PD-1) inhibitors in the treatment of HCC in recent years, the role of programmed cell death ligand 1 (PD-L1) and soluble programmed cell death ligand 1 (sPD-L1), as the ligands of PD-1, in immune escape and their value in predicting prognosis have attracted more and more attention. This article elaborates on the current controversies, consensus, and advances in PD-L1 and sPD-L1 as immune markers in evaluating the prognosis of HCC.
ABSTRACT
Objective To investigate the relationship between molecular biological markers and recombinant human endostatin targeted therapy in non-small-cell lung cancer(NSCLC).Methods 68 cases patients with non-small-cell lung cancer to meet the requirements were randomly divided into group A (n=34)and group B (n=34).Group A received docetaxel and cisplatin(DP)and gefitinib;group B received recombinant human endostatin on the base of group A.The biological markers species,such as,EGFR,KRAS,VEGF,BRCA1,EML4-ALK,ERCC1,β-tubulin and CD3 were detected by immunohistochemical.The types of population for different programs were summarized according to the expression of biological markers and progression free survival (PFS)of the two groups. Results Group B median PFS was significantly longer than that in group A;no matter low or high expression of VEGF and BRCA1,group B median PFS was significantly longer than that in group A(P<0.05);high expression of ERCC1,KRAS,EML4-ALK andβ-tubulin,group B median PFS was significantly longer than that in group A(P<0.05);low expression of EGFR and CD3,group B median PFS was significantly longer than that in group A (P<0.05 ).Conclusion No matter low or high expression of VEGF and BRCA1 ,low expression of KRAS, ERCC1,EML4-ALK and β-tubulin and high expression of EGFR and CD3 in patients with non-small cell lung cancer may be more sensitive to the treatment of DP and gefitinib combined with recombinant human endostatin.